B-cell Malignancies Clinical Trial
Official title:
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies
The purpose of this study is to evaluate the long-term safety of zanubrutinib regimens in participants with B-cell malignancies who participated in a BeiGene parent study for zanubrutinib.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02343120 -
Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT02018861 -
A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)
|
Phase 1/Phase 2 | |
| Terminated |
NCT03701438 -
Immune Response to Influenza Vaccine in Adults With B-cell Malignancies Treated With Idelalisib
|
||
| Completed |
NCT02327078 -
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
|
Phase 1/Phase 2 | |
| Completed |
NCT04551963 -
Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies
|
Phase 1 | |
| Recruiting |
NCT05683717 -
A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies
|
Phase 1 | |
| Completed |
NCT01775631 -
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
|
Phase 1 | |
| Active, not recruiting |
NCT01905813 -
Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies
|
Phase 1 | |
| Recruiting |
NCT05275504 -
Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies
|
Phase 1 | |
| Active, not recruiting |
NCT02457598 -
Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies
|
Phase 1 | |
| Recruiting |
NCT03050190 -
A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03125577 -
Combination CAR-T Cell Therapy Targeting Hematological Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04509700 -
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
|
Phase 2 | |
| Not yet recruiting |
NCT03642496 -
Clinical Study of ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies
|
Early Phase 1 | |
| Completed |
NCT00983619 -
A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies
|
Phase 1/Phase 2 |